A targeted RNA therapy boosts VEGF‑A in transplanted beta cells, accelerating blood-vessel growth and improving islet survival and glucose control for Type 1 diabetes.
Netflix has a new original movie out with a 100% Rotten Tomatoes critic review score and an absolutely stellar cast.

Start with the Volkswagen, because it is the one that should give Europe pause. SAIC Volkswagen, the joint venture with China’s state-owned SAIC Motor, opened preorders for the ID. Era 5S saloon this week. The introductory price is 115,900 yuan, which …

Today on Decoder, I’m talking with Hayden Field, The Verge’s senior AI reporter, about a question that’s been rocketing around the tech industry for the past week: Is Google losing the AI race? That’s because last week Google announced a bombshell reorganization of its AI division, Google DeepMind. Jeff Dean, the company’s chief scientist, is […]

Almost every AI business sells a product. Someone builds a model or a tool, licenses it, and hopes the customer works out what to do with it. Thrive Holdings inverts that. It buys accounting firms and IT services companies outright, puts its own engine…

Code review is the step where somebody reads a change before it ships. A developer proposes an edit, opens what the trade calls a pull request, and a colleague checks it for bugs and security holes. It is slow and unglamorous work. Until recently it wa…

Nuclear reactors need water. They sit beside rivers and coastlines for a reason. The water carries heat away from the core. When it runs low or runs warm, the reactor has to power down. That is happening across Europe right now. On Thursday, Romania’s …
Jacob Fortinsky, the CEO and cofounder of the new prediction market Novig, says his outfit isn’t like those other markets. You know the ones.

Accel is a venture capital firm. It gives money to startups early, usually before anyone else has, and takes a stake in return. It has done this since 1983, and it wrote the first institutional cheque into Atlassian, CrowdStrike, Flipkart and Slack. On…